Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.

• Publication year

  2010

• Venue

  Journal of Translational Medicine

• Publication date

  2010-07-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1479-5876-8-67PMID 20630094PMCID 2917408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer.

  2016cited by this paper
• Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

  2010cited by this paper
• PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

  2010cited by this paper
• BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.

  2009cited by this paper
• BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells

  2008cited by this paper
• B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis

  2007cited by this paper
• Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.

  2007cited by this paper
• BRAF and NRAS mutations in melanoma and melanocytic nevi

  2006cited by this paper
• Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

  2005influential reference
• BRAF Mutation: A Frequent Event in Benign, Atypical, and Malignant Melanocytic Lesions of the Skin

  2003cited by this paper

• Neoadjuvant Treatment Strategies in Gastrointestinal Stromal Tumors.

  2026cites this paper
• Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers

  2025cites this paper
• Neoadjuvant Treatment Strategies in Gastrointestinal Stromal Tumors

  2025cites this paper
• Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting

  2024cites this paper
• Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers

  2024cites this paper
• Disszeminált cutan melanoma célzott terápiájának hatására kialakult cisztoid makulaödéma kezelése és nyomon követése

  2024cites this paper
• Modeling Extraordinary Response Through Targeting Secondary Alterations in Fusion-Associated Sarcoma

  2024cites this paper
• Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review

  2024cites this paper
• Detection of human papillomavirus (HPV) in malignant melanoma.

  2024cites this paper
• The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

  2024cites this paper
• Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response.

  2024cites this paper
• Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential

  2024cites this paper
• Contributions of replicative and translesion DNA polymerases to mutagenic bypass of canonical and atypical UV photoproducts

  2023cites this paper
• An updated literature on BRAF inhibitors (2018–2023)

  2023cites this paper
• PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism

  2023cites this paper
• Detecting recurrent passenger mutations in melanoma by targeted UV damage sequencing

  2023cites this paper
• Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma

  2022cites this paper
• A radiologist’s guide to novel anticancer therapies in the era of precision medicine

  2022cites this paper
• BRAF Immunohistochemical Studies of Pediatric Conjunctival Lesions

  2022cites this paper
• Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma

  2022cites this paper
• Melanoma therapeutics: a literature review

  2022cites this paper
• Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics

  2022cites this paper
• Cytologic diagnosis of metastatic melanoma by FNA: A practical review

  2021cites this paper
• Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study

  2021cites this paper
• The Genetics of Early-Stage Melanoma in a Veteran Population

  2021cites this paper
• Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era

  2021influential citation
• A Review of Epidemiology and Cancer Biology of Malignant Melanoma

  2021cites this paper
• BRAF Gene and Melanoma: Back to the Future

  2021cites this paper
• Benchmarking 50 classification algorithms on 50 gene-expression datasets

  2021cites this paper
• Signal pathways of melanoma and targeted therapy

  2021cites this paper
• Determination of dabrafenib and trametinib in serum by dispersive solid phase extraction with multi-walled carbon nanotubes and capillary electrophoresis coupled to ultraviolet/visible detection

  2021cites this paper
• Genetic Testing

  2021influential citation
• Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies

  2021cites this paper
• Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment

  2020cites this paper
• Current State of Target Treatment in BRAF Mutated Melanoma

  2020cites this paper
• Cancer stem cells, plasticity, and drug resistance

  2020cites this paper
• A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma

  2020cites this paper
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2020cites this paper
• Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.

  2020cites this paper
• Atypical UV Photoproducts Induce Non-canonical Mutation Classes Associated with Driver Mutations in Melanoma

  2020cites this paper
• Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database

  2020cites this paper
• The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape

  2020cites this paper
• High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens

  2020cites this paper
• Molecular and Immunohistochemical Analysis of BRAF gene in Primary Cutaneous Melanoma: Discovery of novel mutations.

  2020cites this paper
• Evolution of molecular targets in melanoma treatment.

  2020cites this paper
• Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

  2020cites this paper
• Absence of BRAFV600E Immunohistochemical Expression in Sporadic Odontogenic Keratocyst, Syndromic Odontogenic Keratocyst and Orthokeratinized Odontogenic Cyst.

  2020cites this paper
• Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA

  2019cites this paper
• Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast

  2019cites this paper
• Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: First findings from Indian malignant melanoma patients.

  2019cites this paper
• Identifizierung von Zielgenen des neuronalen Transkriptionsfaktors Brn3a im Melanom mittels Microarray-Analysen

  2019influential citation
• Dedifferentiated Melanoma With Expression of Cytokeratin and GATA3 in a Patient With History of Breast Carcinoma.

  2019cites this paper
• Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells

  2019cites this paper
• Mathematical Methods for Modelling Biological Heterogeneity

  2019cites this paper
• R

  2019cites this paper
• Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma

  2019cites this paper
• The Role of Long Non-coding RNAs in Melanoma Genesis and Progression

  2019cites this paper
• The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma

  2018influential citation
• INKA, an integrative data analysis pipeline for phosphoproteomic inference of active phosphokinases

  2018cites this paper
• Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma

  2018cites this paper
• Cancer Drug Resistance Cancer stem cells, plasticity and drug resistance

  2018cites this paper
• BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy Effective : August 1 , 2018

  2018cites this paper
• BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy

  2018cites this paper
• BRAF Gene Variant Testing to Select Melanoma or Glioma Patients for Targeted Therapy

  2018cites this paper
• Actin Gamma 1, a new skin cancer pathogenic gene, identified by the biological feature‐based classification

  2018cites this paper
• Cutaneous melanoma: From pathogenesis to therapy (Review)

  2018cites this paper
• Biology and Genomics of LCH and Related Disorders

  2018cites this paper
• Generation and Single-Molecule Characterization of a Sequence-Selective Covalent Cross-Link Mediated by Mechlorethamine at a C-C Mismatch in Duplex DNA for Discrimination of a Disease-Relevant Single Nucleotide Polymorphism.

  2018cites this paper
• Spatio-Genetic and Phenotypic Modelling Elucidates Resistance and Re-Sensitisation to Treatment in Heterogeneous Melanoma

  2018cites this paper
• Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

  2018cites this paper
• Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with BRAF Mutation

  2018cites this paper
• Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing.

  2018cites this paper
• Cutaneous pH landscape as a facilitator of melanoma initiation and progression

  2018cites this paper
• Identification and functional analysis of SOX10 phosphorylation sites in melanoma

  2018cites this paper
• Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations

  2018cites this paper
• Circulating tumour DNA: A non-invasive biomarker for melanoma

  2018cites this paper
• Tumour mutation status and sites of metastasis in patients with cutaneous melanoma

  2017cites this paper
• A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens.

  2017cites this paper
• Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma

  2017cites this paper
• BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence.

  2017cites this paper
• Metastatic melanoma: prognostic factors and survival in patients with brain metastases

  2017cites this paper
• BRAF Mutation and its Effects on Radioiodine Uptake in Patients with Anaplastic Thyroid Carcinoma

  2017cites this paper
• Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.

  2017cites this paper
• An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.

  2017cites this paper
• Leczenie czerniaków BRAF+ w świetle obowiązujących programów lekowych

  2017cites this paper
• BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry

  2017cites this paper
• Osteogenic Melanoma With Desmin Expression

  2017cites this paper
• Concordancia mutacional de BRAF entre melanoma primario cutáneo y sus correspondientes metástasis. Revisión de la evidencia actual

  2017cites this paper
• Treatment of BRAF+ melanoma in light of current drug programs

  2017cites this paper
• Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma

  2017influential citation
• Long non-coding RNAs in cutaneous melanoma: clinical perspectives

  2017cites this paper
• Optimisation of the isolation and identification of circulating melanoma cells

  2017cites this paper
• Bioinformatic identification of novel melanoma drug targets and investigation of potential inhibitors using high throughput screening

  2017cites this paper
• BRAF Gene Mutation Testing to Select Melanoma or Glioma Patients for Targeted Therapy

  2017cites this paper
• Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE

  2017cites this paper
• Novel ultra-sensitive digital PCR assays for screening and detection of rare missense mutations in (proto)-oncogenes

  2017cites this paper
• targeted therapy and Immunotherapy in the treatment of metastatic cutaneous melanoma

  2017cites this paper
• MAGERI: Computational pipeline for molecular-barcoded targeted resequencing

  2017cites this paper
• BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence

  2017cites this paper
• Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.

  2017cites this paper